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Though protamine sulfate is the only approved antidote of unfractionated heparin
(UFH), yet may produce life threatening side effects such as systemic hypotension,
catastrophic pulmonary vasoconstriction or allergic reactions. We have described 40 kDa
dextrans (Dex40) substituted with glycidyltrimethylammonium chloride (GTMAC) as
effective, immunogenically and hemodynamically neutral inhibitors of UFH. The aim of
the present study was to evaluate in mice and rats toxicokinetic profile of the most
promising polymer—Dex40-GTMAC3. Polymer was rapidly eliminated with a half-time of
12.5 ± 3.0min in Wistar rats, and was mainly distributed to the kidneys and liver in mice.
The safety studies included the measurement of blood count and blood biochemistry,
erythrocyte osmotic fragility and the evaluation of the histological alterations in kidneys,
liver and lungs of mice and rats in acute and chronic experiments. We found that
Dex40-GTMAC3 is not only effective but also very well tolerated. Additionally, we found
that protamine may cause overt hemolysis with appearance of permanent changes
in the liver and kidneys. In summary, fast renal clearance behavior and generally low
tissue accumulation of Dex40-GTMAC3 is likely to contribute to its superior to protamine
biocompatibility. Intravenous administration of therapeutic doses to living animals does
not result in the immunogenic, hemodynamic, blood, and organ toxicity. Dex40-GTMAC3
seems to be a promising effective and safe candidate for further clinical development as
new UFH reversal agent.
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INTRODUCTION
Unfractionated heparin (UFH) is mainly utilized in hospitals during the treatment and prevention
of thrombosis, but is associated with an increased risk of bleeding and other adverse effects.
Although, UFH is being replaced by low molecular weight heparins (LMWHs) or fondaparinux
because of the safety reasons, according to the latest reports the Europe heparin market is estimated
to be around USD 2 billion and may reach USD 3 billion in 2022; UFH share is still at around 10%
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(Transparency Market Research, 2015). In contrast to the new
parenteral anticoagulants, UFH is inexpensive and it can be fully
neutralized by protamine sulfate in case of bleeding. Importantly,
UFH, discovered a century ago is one of the oldest drugs,
with very well defined advantages, side effects, and therapeutic
applications (Wardrop and Keeling, 2008). Indeed, the use of
UFH and protamine is essential during many cardiovascular
procedures, such as coronary artery bypass, heart transplant,
cardiac valve repair or repair of congenital heart problems;
their number increased by 28% from 5, 939, 000 in 2000 to
7, 588, 000 in 2010 in USA (Mozzaffarian et al., 2015). Also,
surgical procedures like aortic aneurysm repair, arteriovenous
fistula grafts for hemodialysis, carotid endarterectomy, complex
vascular reconstruction or femoral popliteal bypass often require
co-administration of UFH and protamine (Mahan, 2014).
Protamine sulfate, the only approved antidote for heparin-
based therapies, is a purified mixture of cationic proteins
obtained from the sperm of wild salmon-like species fished
over a specific area off the coast of Honshu Island. This
cationic peptide binds to heparins, which are negatively charged,
to form a complex that lacks anticoagulant activity. Despite
poor therapeutic index, protamine has been used with caution
since 1939, because there is no alternative. Many methods,
such as administration of small or divided doses were tried to
prevent the adverse effects of protamine, which include systemic
hypotension, pulmonary vasoconstriction and allergy reactions,
sporadically leading to cardiovascular collapse and death (Hirsh
et al., 2008). The incidence of mild reactions to protamine is
as high as 16% and that of severe reactions is between 0.2
and 3.0% (Lowenstein et al., 1983; Holland et al., 1984; Katz
et al., 1987; Cook et al., 1992). Additionally, unseen pathological
effects of protamine may contribute to the postsurgical morbidity
and mortality. Therefore, many studies were undertaken in
the past to develop safer replacer of protamine (Bromfield
et al., 2013). The most advanced agents are in the animal
(universal heparin reversal agents, UHRAs) (Shenoi et al., 2014)
or human (idarucizumab) (Pollack et al., 2015) phases of drug
development; andexanet alfa (Lu et al., 2013) and aripazine
(PER977) (Ansell et al., 2014) already finished first clinical trials
and received breakthrough designation from the FDA. In clinical
trials patients’ safety is paramount, therefore potential toxicity
of new candidates for drugs is the most important issue. A
number of compounds that have been primarily introduced as
very effective antidotes of heparins such as delparantag (PMX-
60056) (Mahan, 2014), REG1 Anticoagulation System (Burke,
2015), PM102 (Cushing et al., 2010), virus-like nanoparticles
(VLP) (Gale et al., 2011) or HepArrestTM (Shenoy et al., 1999),
later in the preclinical and even in the clinical trials revealed
unacceptable side effects and failed.
We have recently presented series of different synthetic
water-soluble molecules that directly complex UFH (Kaminski
et al., 2008, 2010, 2011, 2014; Kalaska et al., 2012, 2015).
Dextran with 40 kDa of mean molecular weight substituted with
GTMAC at a ratio of 0.65 GTMAC groups per a glucose unit
(Dex40-GTMAC3), originated from an FDA-approved, generally
nontoxic, biodegradable and inexpensive polysaccharide, did not
elicit detectable immune response at the doses that allowed
complete neutralization of UFH at in vitro and in vivo conditions
(Kalaska et al., 2015). The aim of this study was to provide a
toxicokinetic profile of intravenously injected Dex40-GTMAC3.
We evaluated the safety profile in mice and rats using different
approaches to explore the possible application for restoring
normal blood clotting in heparinized patients.
MATERIALS AND METHODS
Animals and Housing
Animals were purchased and housed in the Centre of
Experimental Medicine of Medical University of Bialystok in
specific pathogen free conditions according to Good Laboratory
Practice rules. Thirty-two male Wistar rats, 34 male NMRI-
Foxn1nu/Foxn1nu mice and 10 BALB/c male mice were used in
all experiments. Animals were housed with a 12 h light/dark cycle
in temperature (22 ± 2◦C) and humidity (55 ± 5%) controlled
room, grouped in cages as appropriate, and allowed to have
ad libitum access to sterilized tap water and a standard chow
(Ssniff R-Z V1324). The animals’ health status was monitored
throughout the experiments by a health surveillance programme
according to Federation of European Laboratory Animal Science
Associations (FELASA) guidelines. The rats andmice were free of
all viral, bacterial, and parasitic pathogens listed in the FELASA
recommendations. All the procedures involving animals and
their care were approved by Local Ethical Committee on Animal
Testing at the Medical University of Bialystok (Permit Numbers
28/2012 and 15/2013) and by First Local Ethical Committee on
Animal Testing at the Polish Academy of Science in Wroclaw
(Permit Number 26/2014) and conducted in accordance with
ARRIVE guidelines (McGrath et al., 2010), directive 2010/63/EU
of the European Parliament and of the Council on the protection
of animals used for scientific purposes and the national laws.
Procedures were conducted in the light phase of cycle in the
surgical room of our laboratory. All animals were euthanized by
pentobarbital injection at the end of experiments.
Materials
Heparin sodium salt from bovine intestinal mucosa (UFH),
protamine (protamine sulfate salt from salmon, grade X),
dextran (MW = 40 kDa from Leuconostoc spp.), sodium
chloride (analytical grade), rhodamine B isothiocyanate
(RBITC, HPLC grade), fluorescein isothiocyanate (FITC,
HPLC grade), glycidyltrimethylammonium chloride (GTMAC,
technical grade), sodium hydroxide (analytical grade), acetone
(analytical grade), pyridine (analytical grade), dimethyl sulfoxide
(analytical grade), dipotassium ethylenediaminetetraacetic acid
(K2EDTA, analytical grade) were purchased from Sigma-Aldrich
(Germany). Isoflurane was purchased from Baxter (Germany).
Pentobarbital, ketamine, xylazine were purchased from Biovet
Pulawy (Poland). Trisodium citrate was purchased from Avantor
Performance Materials, Gliwice, Poland). Ethanol 96% was used
in the study. Dex40-GTMAC3 was synthesized as described
previously (Kaminski et al., 2011; Kalaska et al., 2015). Dex40-
GTMAC3 was fluorescently labeled with RBITC and FITC as
follows. Two hundred and fiftymg of polymer was dissolved in
20ml of warm DMSO and 3 drops of pyridine and 15mg of a
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respective isothiocyanate was added. The mixture was heated to
95◦C for 2 h under continuous stirring. After this time DMSO
was removed by dialysis against water for 6 h, then the product
was precipitated with acetone. The degree of substitution with
the fluorescent probe was∼1% per glucose unit.
The Measurement of Fluorescein-labeled
Dex40-GTMAC3 Concentration in Rats
Three male Wistar rats weighting 213± 3 g were anesthetized by
an intraperitoneal injection of pentobarbital (45mg/kg b.w.) and
placed in a supine position on a heated operation table. Heparin
(300U/kg) or vehicle (PBS) pre-treatment was followed after
3min with fluorescein-labeled Dex40-GTMAC3 administration
via femoral vein in dose of 7.5mg/kg (Figure 1). Approximately
500µl of blood was collected via common carotid artery 5min
prior and at 5, 20, 60, and 120min following heparin or vehicle
injection to measure plasma Dex40-GTMAC3 concentration for
pharmacokinetic assessment. Animals were sacrificed at 120min
by the injection of pentobarbital (45mg/kg b.w.), blood samples
were taken from the heart and organs (liver, small and large
intestine, kidneys, lungs, heart, abdominal aorta, left and right
nucleus, bladder, brain) were collected, weighed, and frozen
at −80◦C. Then, organs were homogenized using an ultrasonic
homogenizer (UP50H Dr. Hielscher GmbH) 50W 33Hz in PBS
buffer at a pH of 7.4 at a ratio of 1 g tissue and 2ml buffer.
Homogenates were centrifuged for 5min at 6000 rpm. The
supernatant was transferred to a cuvette and diluted 3 times.
The measurement was performed at a wavelength of 485 nm
excitation. T½ (terminal elimination half-life) was calculated
by PK Solver Excel add-in program using Non-Compartmental
Analysis of Plasma Data after Intravenous Bolus Input Model.
The Body Distribution of
Rhodamine-Labeled Dex40-GTMAC3 in
Mice
The body distribution of the cationic dextran was measured in
30 NMRI-Foxn1nu/Foxn1nu mice anesthetized with a mixture
of isoflurane and oxygen at a concentration of 3% (maintained
then at a concentration of 1.5–2.5%); 5 mice served as a control
group. Rhodamine-labeled Dex40-GTMAC3 was administered
in dose of 22.5mg/kg b.w. 5min after UFH (300U/kg) to 25
mice and body distribution was measured in 5, 15, 30, 60, and
120min (5 different animals for each time point) using In-vivo
MS FX PRO system (Carestream Health INC., USA). The brain,
lungs, kidneys, heart, liver and spleen were isolated from mice
and their fluorescence was measured ex vivo. The signal intensity
in control group (0.9, 0.9, 1.0, 1.2, and 1.0 I[AU] 107 in livers, 0.2,
0.3, 0.2, 0.2, and 0.2 I[AU]•107 in kidneys, 2.5, 2.8, 2.4, 2.0, and
1.6 I[AU]•106 in lungs, 1.1, 1.5, 1.3, 1.1, and 1.3 I[AU]•106 in
spleens, 0.4, 0.7, 0.7, 0.9, and 0.5 I[AU]•106 in hearts, 1.4, 2.8, 2.4,
2.5, and 2.5 I[AU]•106 in brains, for 5, 15, 30, 60, and 120min,
respectively) was subtracted from the presented results.
Erythrocyte Osmotic Resistance Assay
The osmotic resistance was measured according to the method
described by Hunter (1940) in our modification (Tankiewicz
et al., 2005). Briefly, blood collected from heart of Wistar rats
on K2-EDTA as anticoagulant was mixed gently for 30min in
room temperature with different concentrations of protamine
(1, 10, 100µg/ml) or Dex40-GTMAC3 (1, 10, 100µg/ml). Then,
10µl of blood was added to 2ml saline solution in range
of concentration from 10 to 150mM. The suspension was
allowed to stand at room temperature for 30min and was
centrifuged at 1000 g for 5min at 4◦C. The absorbance of received
supernatants was determined in microplate reader (Dynex
Tech., USA) at 540 nm. Mean osmotic resistance (MOR50) is
the concentration of NaCl, at which 50% of red cells were
lysed.
Collection of Organs in Short-Term
Observation in Mice
Ten male BALC/c mice weighing 24.5 ± 0.6 g (no significant
difference between groups) and aged 8–10 weeks were randomly
divided into 4 groups (2–3 per experimental group), anesthetized
with a mixture of ketamine (125mg/kg b.w.) and xylazine
(12.5mg/kg b.w.). UFH was administered into the tail vein
in dose of 300 U/kg b.w. alone or followed (3min) by
intravenous administration of Dex40-GTMAC3 (7.5mg/kg b.w.)
or protamine (3mg/kg b.w.). Fragments of organs (liver, kidney
and lungs) were collected 1 h after drug administration, fixed
in Bouin’s fluid and processed routinely for embedding in
paraffin. Sections were cut at 4µm in thickness, and stained
by hematoxylin and eosin (H&E) for routine histological
examination.
Histological Evaluation of Liver and Lungs
in Long-Term Observation
Twenty-seven male Wistar rats weighing 220–300 g were
anesthetized with a mixture of isoflurane and oxygen at a
concentration of 2–4% (maintained then at a concentration
of 1.5–2.5%). Animals were randomly divided into 4 groups
(5–7 per experimental group). UFH was administered into
the tail vein in dose of 300 U/kg b.w. alone or followed
(3min) by intravenous administration of Dex40-GTMAC3
(7.5mg/kg b.w.) or protamine (3mg/kg b.w.) (Figure 2).
Vehicle (PBS) treated rats served as a control group. Then,
after 6 h, 7, 14, 28 days, the animals were weighed, again
anesthetized with a mixture of isoflurane and oxygen, and 0.3ml
of blood was collected from the tail artery on the standard
anticoagulant for the evaluation of hematological parameters:
white blood cells (WBC), red blood cells (RBC), hemoglobin
(HGB), hematocrit (HCT), mean corpuscular volume (MCV),
mean corpuscular hemoglobin (MCH), mean corpuscular
hemoglobin concentration (MCHC), platelets (PLT) in a blood
analyzer (ABC Vet, Horiba, Germany). Zero point seven ml of
blood was centrifuged and biochemical parameters: aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
creatinine (CREA), amylase (AMYL), alkaline phosphatase
(ALP), creatine kinase (CPK) were measured in serum
by automated clinical biochemical analyzer (Mindray BS
120, Germany). After 28 days rats were anesthetized with
pentobarbital at the dose of 45mg/kg b.w. Blood was taken
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FIGURE 1 | Schematic representation of the study protocol. PK = the measurement of plasma protamine/fluorescein-labeled Dex40-GTMAC3 for
pharmacokinetic characterisation.
FIGURE 2 | Schematic representation of the study protocol. Diagram shows the time course of events from vehicle or UFH administration following
neutralization with Dex40-GTMAC3 or protamine injected in rat tail vein through blood sampling time points to the end of the experiment with the collection of organs.
from the right ventricle to the standard anticoagulant. A
part of blood was used for morphological analyses while the
remaining amount has been used to receive plasma and serum,
which were frozen at a temperature of −80◦C. The same
fragment of the liver lobe and kidney were collected from
each rat for histological examination. The lungs were collected
in whole. Immediately after thoracotomy, Bouin’s fluid was
administered with syringe into the trachea to smoothen the
pulmonary pleura of isolated lungs. After fixation fragment of
the lung (the anterior part of the superior pulmonary lobe) was
collected.
Histological Evaluation of Liver, Kidneys,
and Lungs
All tissues were routinely placed in paraffin blocks and
then sectioned by a Leica 2025 rotating microtome. Sections
were cut into 4µm in thickness, and later stained with
hematoxylin and eosin (H&E) were evaluated under a light
microscope.
Statistical Analysis
In the study n refers to the number of animals in each
experimental group. For in vivo experiment, the experimental
unit was an individual animal. The data were analyzed by
GraphPad Prism 6 using the non-parametric Mann-Whitney test
and presented as a median with lower and upper limits. Analysis
of variance (ANOVA) was used to compare differences between
means presented as mean± SD, whenever data passed normality
test. P-values less than 0.05 were considered significant. Half-
time and C0 were estimated by non-compartmental methods
(Beyerle et al., 2014). Fisher exact test with post-hocHolm p-value
adjustment was applied to compare proportions between groups
pairwise (Table 3).
RESULTS
The Concentration of Fluorescein-Labeled
Dex40-GTMAC3 in Rats
The concentration of Dex40-GTMAC3 in plasma declined
shortly after administration. After 60min the amount of the
circulating polymer was 5.8% of the amount measured in
5min. T½ was 12.5 ± 3.03min, whereas C0 was 126.7µg/ml
(determined automatically by extrapolation of the curve)
(Figure 3). We found a signal of fluorescein-labeled Dex40-
GTMAC3 in liver (1st rat = 38.90, 2nd rat = 13.34 and 3rd
rat = 40.12) and kidneys (1st rat = 32.57, 2nd rat = 15.34 and
3rd rat = 61.34). High autofluorescence of heart and stomach in
comparison to vehicle treated rats prevented the precise detection
of polymer in these tissues. In the pancreas, spleen, brain, and
lung fluorescence signal of fluorescein-labeled protein was below
the detection limit.
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FIGURE 3 | Plasma concentration of Dex40-GTMAC3 (7.5mg/kg)
administered as an intravenous single injection 3min following UFH
(300 U/kg) administration. Results are shown as mean ± SD.
Distribution of Rhodamine-Labeled
Dex40-GTMAC3 in Mice
The maximum fluorescence intensity was observed in the liver,
kidneys and lungs 5min after intravenous administration of
Dex40-GTMAC3 (Figure 4A). The signal from liver and kidney
of animals treated with rhodamine-labeled Dex40-GTMAC3 was
higher than in vehicle-treated group (examples are presented
in Figure 5). Then, the fluorescence in these organs decreased
slightly, but remained at similar level for 2 h. Over the course
of 120min we found slight, but higher than recorded for vehicle
treated animals signal of rhodamine-labeled Dex40-GTMAC3
localized in heart, brain, and spleen (Figure 4B).
Influence of the Dex40-GTMAC3 on
Erythrocyte Osmotic Resistance
The initial hemolysis (>5%) occurred at 150mmol/l saline
solution in all samples. We observed a steadily increasing
susceptibility to hypotonic lysis in blood samples incubated
with increasing concentrations of test substances. Differences
were most significant at NaCl concentrations of 80–90mmol/l.
MOR50 was 85.16 ± 3.82 in control group. Starting from
concentration of 10µg/ml Dex40-GTMAC3 significantly
decreased MOR50, whereas protamine slightly, but significantly
increased MOR50starting from concentration of 1µg/ml
(Figure 6).
Influence of the Dex40-GTMAC3 on Body
Weight
No deaths were reported during 1 month observation. No drug-
related clinical signs of toxicity, effects on food consumption or
ocular changes were observed during the study. No significant
differences were noted in mean baseline body weights between
randomized treatment groups (Figure 7). The mean body weight
for control rats increased from 193 ± 17.5 g at baseline to
314.7± 10.9 g at day 28 (mean body weight gain, 121.1± 16.6 g)
and it was similar in rats receiving heparin (300U/kg) followed
by Dex40-GTMAC3 (7.5mg/kg) (128.3 ± 9.8 g) or protamine
(134.4± 25.5 g).
FIGURE 4 | The intensity of fluorescence measured in kidneys and liver
(A) or lungs, heart, spleen, and brain (B) isolated from mice treated
intravenously with rhodamine-labeled Dex40-GTMAC3 (22.5mg/kg),
3min following UFH (300 U/kg) administration. The signal intensity in
control group (0.9, 0.9, 1.0, 1.2, and 1.0 I[AU]•107 in livers, 0.2, 0.3, 0.2, 0.2,
and 0.2 I[AU]•107 in kidneys, 2.5, 2.8, 2.4, 2.0, and 1.6 I[AU]•106 in lungs,
1.1, 1.5, 1.3, 1.1, and 1.3 I[AU]•106 in spleens, 0.4, 0.7, 0.7, 0.9, and 0.5
I[AU]•106 in hearts, 1.4, 2.8, 2.4, 2.5, and 2.5 I[AU]•106 in brains, for 5, 15,
30, 60, and 120min, respectively) was subtracted from the presented results.
Results are presented as median, upper/lower limits.
Influence of the Dex40-GTMAC3 on Blood
Parameters
WBC, RBC, HGB, HCT, MCV, MCHC, PLT were counted in
whole blood following single intravenous administration of UFH
(300U/kg) alone or followed by Dex40-GTMAC3 (7.5mg/kg) or
protamine (3mg/kg) after 7, 14, and 28 days. The injection of
the tested compound did not change the blood parameters in all
time points (Table 1). We found slight, but significant changes of
some parameters between time points within groups as a result
of differences in procedures, i.e., blood collection from rat tail
vs. heart after chest opening. Furthermore, blood cell count in all
experimental groups remained within the normal range (Giknis
and Clifford, 2008).
Influence of the Dex40-GTMAC3 on
Biochemical Parameters
To examine the effect of Dex40-GTMAC3 on hepatic and
renal functions we measured ALT and AST activities in the
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FIGURE 5 | The intensity of fluorescence in example livers (A) and kidneys (B) collected from mice treated intravenously with rhodamine-labeled
Dex40-GTMAC3 (22.5mg/kg), 3min following UFH (300 U/kg) administration in the consecutive time points. The signal intensity in control group (0.9, 0.9,
1.0, 1.2, and 1.0 I[AU]•107 in livers and 0.2, 0.3, 0.2, 0.2, and 0.2 I[AU]•107 in kidneys for 5, 15, 30, 60, and 120min, respectively) was subtracted from the
presented results.
TABLE 1 | Hematological analysis of whole blood samples from rats treated with UFH (300U/kg) alone or followed by Dex40-GTMAC3 (7.5mg/kg) or
protamine (3mg/kg).
Parameters (unit) Time (days) Vehicle UFH 300 U/kg UFH 300 U/kg +
Dex40-GTMAC3 7.5mg/kg
UFH 300 U/kg +
Protamine 3.0mg/kg
WBC (103/mm3 ) 7 6.4 (6.3–13.0) 8.3 (6.7–12.5) 8.9 (5.2–13.2) 9.8 (6.5–15.3)
14 10.5 (7.4–13.7) 12.6 (7.4–17.6) 10.3 (5.9–15.1) 9.2 (6.1–16.2)
28 4.5* (3.1–10.1) 6.0*∧∧ (3.7–7.9) 5.6*∧ (4.4–6.8) 5.2**∧ (3.9–6.5)
RBC (103/mm3 ) 7 5.9 (5.2–6.6) 6.3 (5.8–6.5) 6.0 (4.9–6.9) 6.1 (5.7–6.4)
14 6.7 (5.0–7.2) 6.7* (6.0–7.3) 6.5 (5.2–6.3) 6.4 (6.1–6.7)
28 7.1* (7.0–7.4) 6.9** (6.5–7.5) 7.0** (6.6–7.8) 6.9** (6.0–7.2)
HGB (g/dl) 7 13.6 (12.3–15.0) 14.0 (13.9–14.5) 14.0 (11.8–15.1) 14.1 (13.7–14.7)
14 15.1* (15.0–15.7) 14.7* (14.3–15.6) 14.6 (11.7–16.3) 14.8 (14.0–15.4)
28 14.7 (14.6–15.7) 14.6 (13.1–15.3) 14.8* (14.5–15.9) 14.3 (14.3–14.9)
HCT (%) 7 35.7 (31.9–39.1) 36.9 (36.2–38.5) 36.7 (35.0–39.7) 36.9 (35.3–38.2)
14 39.5* (38.9–41.3) 38.9* (37.1–41.9) 38.4 (30.9–42.0) 38.4 (36.2–40.4)
28 40.1* (38.8–41.4) 37.8 (34.2–41.3) 39.6* (38.7–44.0) 38.9** (37.9–40.0)
MCV (µm3) 7 59.0 (58.0–61.0) 59.0 (58.0–63.0) 60.0 (57.0–63.0) 60.0 (59.0–62.0)
14 59.0 (58.0–60.0) 57.5 (57.0–61.0) 59.0 (56.0–61.0) 59.0 (59.0–61.0)
28 56.0*∧ (55.0–58.0) 55.5**∧ (54.0–57.0) 57.0** (54.0–59.0) 57.0**∧∧ (54.0–58.0)
MCH (pg) 7 22.8 (22.1–23.8) 22.4 (21.9–24.1) 23.1 (21.3–24.5) 23.4 (22.0–24.1)
14 22.4 (21.8–23.5) 22.0 (21.3–23.6) 22.6 (20.7–23.5) 23.0 (22.6–23.6)
28 21.1**∧ (20.5–21.9) 20.8**∧∧ (20.1–21.4) 21.3**∧ (19.9–21.9) 20.9**∧∧ (19.7–22.0)
MCHC (g/dl) 7 38.1 (37.4–38.7) 38.1 (37.4–38.3) 38.0 (37.6–39.4) 38.8 (36.7–39.7)
14 38.2 (37.9–38,9) 38.1 (37.1–38.6) 38.2 (37.3–38.8) 38.9 (38.2–39.4)
28 37.5 (36.4–38.3) 37.3 (35.3–38.3) 36.9* (32.3–38.8) 37.3*∧∧ (36.0–37.8)
PLT (103/mm3) 7 415.0 (390.0–546.0) 435.0 (366.0–591.0) 432.0 (361.0–637.0) 432.0 (380.0–658.0)
14 486.0 (211.0–658.0) 418.0 (287.0–602.0) 426.0 (285.0–689.0) 581.0 (336.0–699.0)
28 470.0 (406.0–537.0) 444.0 (395.0–490.0) 431.0 (323.0–571.0) 425.0 (311.0–545.0)
PBS (vehicle) treated rats served as a control group.
WBC, white blood cell count; RBC, red blood cell count; HGB, hemoglobin; HCT, haematocrit; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean
corpuscular hemoglobin concentration; PLT, platelet count. Results are shown as median with lower and upper limits. *p < 0.05, **p < 0.01 vs. 7 days; ∧p < 0.05, ∧∧p < 0.01 vs. 14
days, Mann-Whitney test.
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FIGURE 6 | Mean osmotic resistance (MOR50) exposed to
Dex40-GTMAC3 and protamine. Ten microliter of whole blood in 2ml
of increasing concentration of NaCl were incubated at room temperature
in the absence (control) and in the presence of 1.0, 10, and 100µg/ml
tested compounds. Degree of hemolysis was calculated from the 540 nm
absorbance of the supernatant after centrifugation of the erythrocyte
suspensions. The results are expressed as mean percentage of total
hemolysis in comparison to vehicle ± SD. **p < 0.01, ***p < 0.001 vs.
vehicle, Mann-Whitney test.
FIGURE 7 | Mean body weight from baseline to day 28. Results are
shown as mean ± SD.
serum collected from rats that had been intravenously injected
with heparin (300 U/kg) alone or followed by Dex40-GTMAC3
(7.5mg/kg) or protamine (3mg/kg) 6 h, 14, and 28 days
before collection. PBS (vehicle) treated rats served as a control
group. Additionally, ALP, AMYL, CPK, and CREA activities
were measured. Blood biochemistry did not change in all
time points (Table 2) and no statistically significant changes
in measured parameters were found, compared with vehicle-
treated rats. Similarly to blood count we found significant
changes in ALT, ALP, AMYL, and CREA between time points
within groups.
Organs Morphology
To determine the effect of Dex40-GTMAC3 and protamine
on the rodent tissues, we examined liver, lungs and kidneys
histology 1 h (mice) and 28 days (rats) after the termination of the
experimental procedure. Routine histopathological examination
showed normal liver, kidneys and lungs morphology of the
PBS-injected animals in both groups, sacrificed 1 h and 28
days after vehicle administration. Specimens of the examined
organs in both groups of animals did not show any pathological
features. Though the image of the lung, kidney and liver lobules
construction of UFH-treated animals was preserved, yet 1 h after
UFH injection, the analysis of lung showed slight congestion
of intra-acinar vessels and eosinophil-bronchial epithelial cell
interaction (Figures 8–13).
In microscopic examination histological changes were seen in
the lungs, liver, and kidneys of rats treated with Dex40-GTMAC3
in acute experiment. Histopathologically, lesion characterized by
engorgement of blood vessels and an increase of eosinophilic
cytoplasm some cells of the lungs, liver and kidneys. Liver
histology of rats in acute Dex40-GTMAC3 intoxication showed
little vacuolar degeneration of hepatocytes and local leukocytic
infiltration around central vein. Morphological evaluation of
the lungs of rats receiving Dex40-GTMAC3 showed moderate
vascular and interstitial lung congestion and some epithelial cells
lining the airways showed strongly eosinophilic cytoplasm. There
was slight vacuolization of proximal tubular cells. It appears that
these alterations are reversible. Twenty eight days after Dex40-
GTMAC3 injection we still observed slight vacuolation and
ballooning enlargement of hepatocytes with preserved central
location of the cell nucleus (Table 3). Also, lymphocytes were
locally found within hepatic parenchyma without associated
cellular necrosis (Figures 8–13).
In contrast to the UFH- and PBS-treated groups, the
histological outline of the lungs in the protamine-treated group
revealed strong alveolar hemorrhage. The enlargement of the
alveolar sacs was also found. We noticed faded lobular structure
of the liver with necrotic foci. In the cytoplasm of hepatocytes
we found numerous fatty vacuoles corresponding to the fatty
degeneration. There were also erythrocytes in blood vessels
and the liver sinusoids. Necrotic lesions were also observed
28 days after administration of protamine. In kidneys we
observed vacuolation and sometimes complete exfoliation of
epithelial cells lining the tubular part of the nephron. Around
the renal corpuscle and along the blood vessel infiltration of
inflammatory cells could be observed. In some animals in
the study group histopathological changes were very severe,
including a noticeable damage of the cell nuclei (Figures 8–13,
Table 3).
DISCUSSION
During the past six decades dextrans have been extensively
used as plasma volume expanders because of their high
biocompatibility and biological inertness resulting from their
uncommon poly-(α-D-1,6-glucose) linkage. We previously
reported that 40 kDa dextrans with the degree of substitution
Frontiers in Pharmacology | www.frontiersin.org 7 March 2016 | Volume 7 | Article 60
Sokolowska et al. The Toxicokinetics of Cationically-Modified Dextran
TABLE 2 | Biochemical analysis of serum samples from rats treated with UFH (300 U/kg) alone or followed by Dex40-GTMAC3 (7.5mg/kg) or protamine
(3mg/kg).
Parameters (unit) Time Vehicle (PBS) UFH 300 U/kg UFH 300 U/kg +
Dex40-GTMAC3 7.5mg/kg
UFH 300 U/kg +
Protamine 3.0mg/kg
ALT (U/L) 6 h 44.0 (38.0–54.0) 46.0 (40.0–63.0) 48.0 (39.0–60.0) 49.0 (41.0–59.0)
14 days 52.0 (43.0–68.0) 59.0* (50.0–70.0) 57.0* (51.0–63.0) 54.0 (48.0–58.0)
28 days 38.0∧∧ (31.0–44.0) 37.0**∧∧ (28.0–49.0) 34.0**∧∧∧ (28.0–41.0) 38.0**∧∧ (31.0–41.0)
AST (U/L) 6 h 69.5 (62.0–104.0) 77.0 (54.0–88.0) 67.0 (48.0–93.0) 80.0 (50.0–113.0)
14 days 67.5 (64.0–69.0) 73.0 (66.0–92.0) 67.0 (62.0–86.0) 65.0 (61.0–74.0)
28 days 68.0 (58.0–78.0) 66.0 (57.0–81.0) 68.0 (49.0–85.0) 67.0 (54.0–82.0)
ALP (U/L) 6 h 328.0 (307.0–334.0) 377.0 (231.0–426.0) 288.0 (259.0–357.0) 302.5 (257.0–405.0)
14 days 299.0 (367.0–445.0) 289.0 (204.0–340.0) 246.5 (211.0–399.0) 273.0 (217.0–388.0)
28 days 149.0*∧∧ (132.0-178.0) 155.0***∧∧∧ (112.0–164.0) 128.0** (110.0–175.0) 140.0**∧∧ (112.0–176.0)
AMYL (U/L) 6 h 831.0 (781.0–940.0) 877.0 (772.0–1080.0) 965.0 (845.0–976.0) 873.0 (843.0–937.0)
14 days 862.0 (768.0–881.0) 801.0 (709.0–973.0) 841.5 (833.0–991.0) 874.5 (820.0–961.0)
28 days 854.0 (816.0–892.0) 755.0 (740.0–999.0) 807.0* (681.0–894.0) 818.0 (755.0–943.0)
CREA (mg/dL) 6 h 0.51 (0.43–0.51) 0.46 (0.43–0.53) 0.44 (0.42–0.46) 0.45 (0.44–0.45)
14 days 0.45 (0.45–0.47) 0.47 (0.43–0.49) 0.47** (0.46–0.49) 0.46 (0.45–0.47)
28 days 0.52∧ (0.5–0.52) 0.49∧ (0.48–0.52) 0.49** (0.48–0.52) 0.49* (0.46–0.57)
CPK (U/L) 6 h 416.5 (321.0–512.0) 419.0 (179.0–631.0) 343.0 (196.0–772.0) 467.5 (183.0–667.0)
14 days 344.0 (252.0–687.0) 399.5 (277.0–550.0) 284.0 (206.0–531.0) 312.0 (226.0–425.0)
28 days 387.5 (249.0–588.0) 270.0 (127.0–817.0) 396.5 (168.0–515.0) 341.0 (234.0–676.0)
PBS (vehicle) treated rats served as a control group.
AST, aspartate transaminase; ALT, alanine transaminase; CREA, creatinine; AMYL, amylase; ALP, alkaline phosphatase; CPK, creatine kinase. Results are shown as a median with lower
and upper limits. *p < 0.05, **p < 0.01, ***p < 0.001 vs. 6 h; ∧p < 0.05, ∧∧p < 0.01, ∧∧∧p < 0.001 vs. 14 days, Mann-Whitney test.
TABLE 3 | Summary of notable histological abnormalities in the liver, lungs, and kidneys of rats recorded 28 days after drug administration.
Vehicle (PBS) UFH 300 U/kg UFH 300 U/kg + Dex40-GTMAC3 7.5mg/kg UFH 300 U/kg + Protamine 3mg/kg
Lungs (total examined) 6 7 7 7
Lung congestion (n) 0 4 6* 7*
Liver (total examined) 6 7 7 7
Hepatocelullar vacuolation (n) 0 0∧ 7* 0∧
Hepatocellular fatty vacuoles (n) 0 0 0 7*,∧
Hepatocellular necrotic foci (n) 0 0 0 7*,∧
Kidneys (total examined) 6 7 7 7
Vacuolation of tubular cells (n) 0 0∧ 7* 7*
PBS (vehicle) treated rats served as a control group. *p < 0.05 vs. PBS; ∧p < 0.05 vs. UFH 300 U/kg + Dex40-GTMAC3 7.5mg/kg, Fisher exact test with post-hoc Holm p-value
adjustment.
with cationic groups of 0.5 (Dex40-GTMAC2) and 0.65 (Dex40-
GTMAC3) per glucose unit effectively reversed anticoagulant and
antithrombotic action of heparin in rodents without inducing
immunogenic response (Kalaska et al., 2012, 2015). However,
Dex40-GTMAC2 given alone in a therapeutic dose significantly
decreased blood pressure, whereas Dex40-GTMAC3 did not, but
further escalating of dose revealed similar hypotensive properties
(Kalaska et al., 2015). Thus, we aimed to estimate the body
distribution and potential toxicity of Dex40-GTMAC3 to further
explore its pharmacological effects.
In the present study we demonstrated that Dex40-GTMAC3
displays a favorable to protamine safety profile in rodents. We
found fast renal clearance behavior and low tissue accumulation
of Dex40-GTMAC3. New heparin reversing agent was very well
tolerated by rats up to 28 days after single intravenous injection:
body weight, blood count and blood biochemistry remained
unchanged. Acute and long-lasting histological alterations in
lungs, kidneys and liver of heparinized rats and mice were less
pronounced in Dex40-GTMAC3 treated group in comparison
to protamine. Additionally, we showed that single injection
of protamine might lead to permanent damage of liver and
kidneys.
We found that fluorescein-labeled Dex40-GTMAC3 is rapidly
eliminated from the rat plasma with the circulation half-time
about 12min. If we calculated the half-time based on the body
mass-to-surface area ratio (37 for humans and 6 for rats; Regan-
Shaw et al., 2008), it could be 6 times longer in humans. Half-time
of unmodified dextran used as volume expander with a mean
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FIGURE 8 | Pulmonary changes in the male mice 1h after drug
administration. Photomicrographs of histological sections of lungs from mice
after 1 h of treatment with UFH 300U/kg (A,B), UFH + Dex40-GTMAC3
7.5mg/kg (C,D), and UFH + protamine 3mg/kg (E,F). Images (A,C,E) were
taken using the 100× magnification and images (B,D,F) were taken using
200× magnification. Arrowheads indicate congestion.
molecular weight of 40 kDa varies between 2 and 9 h in humans
(Klotz and Kroemer, 1987; Tobias, 2005; Smith et al., 2011). High
deviation is probably related to the fact, that dextran 40 kDa is a
heterogeneous mixture of different chains weighting from 10 to
80 kDa (Mehvar et al., 1994). Interestingly, protamine half-time
is very short and similar in humans and rats. In animals it is
around 24min in the absence and 18min in the presence of UFH
(Delucia et al., 1993), whereas in humans it is approximately
7.4min (Butterworth et al., 2002).
We used Carestream In VivoMSFXPRO R© system, tomonitor
location of labeled-Dex40-GTMAC3 fluorescence signal in the
living mouse. Similarly to unsubstituted dextrans (Mehvar et al.,
1994), we found the highest concentration of Dex40-GTMAC3
in the liver and kidneys of rats and mice. In humans about
70% of an intravenous dose of unmodified 40 kDa dextran
is excreted by kidneys within 24 h. The remaining 30% is
retained or metabolized (Howard et al., 1955) by different
exo- and endodextranases (α-1-glucosidases) present at higher
concentration in the liver (Lake et al., 1985). In comparison,
protamine given intravenously distributes rapidly to kidneys,
lungs, and heart (Delucia et al., 1993).
We used commercially available fluorophores covalently
attached to the tested polymer to determine Dex40-GTMAC3
concentration in the biological samples. Although, it can be
easily detected in fluorometer, it does not allow distinguishing
between the parent macromolecule and its possible degradation
FIGURE 9 | Hepatocellular changes in the male mice 1h after drug
administration. Photomicrographs of histological sections of the mouse liver
isolated 1 h after the administration of UFH 300U/kg (A,B), UFH +
Dex40-GTMAC3 7.5mg/kg (C,D), and UFH + protamine 3mg/kg (E,F).
Images (A,C,E) were taken using the 100× magnification and images (B,D,F)
were taken using 200× magnification. Arrowheads indicate congestion;
arrows indicate necrotic foci.
products. Negatively charged fluorescein theoretically could
also interfere with hepatic kinetics of Dex40-GTMAC3/UFH
complexes. On the other hand the substitution of Dex40-
GTMAC3 with fluorescein was very low. We also used second
fluorophore—rhodamine B to confirm organ distribution of
Dex40-GTMAC3. Based on this method, we think that the body
distribution and elimination of cationically-modified dextrans
is similar to that of unmodified dextrans (Larsen, 1989; Burns
et al., 1995; Mehvar, 2000; Dhaneshwar et al., 2006). The fast
renal clearance behavior and generally low tissue accumulation
of Dex40-GTMAC3 is likely to contribute to its superior to
protamine biocompatibility.
Because of the cationic nature, protamine may disrupt
erythrocyte membrane and induce hemolysis by an interaction
with the anionic surface of a cell (Carroll et al., 1959), which
may reside in the lipoprotein component (Becker, 1961). The
molecular weight and the balance between hydrophobic and
hydrophilic groups of cationic polymers prompted us to test
their potential blood toxicity, although we did not previously
observe significant changes under microscope (Kaminski et al.,
2010). Thus, before performing in vivo studies we assayed
Dex40-GTMAC3 for potential hemolytic effects to compare
them with those of protamine. We found small (not more
than 3%) difference in erythrocyte osmotic resistance after
incubation with both agents, in slight favor of Dex40-GTMAC3,
Frontiers in Pharmacology | www.frontiersin.org 9 March 2016 | Volume 7 | Article 60
Sokolowska et al. The Toxicokinetics of Cationically-Modified Dextran
FIGURE 10 | Changes in cortical (A,C,E) and indigenous (B,D,F) kidney
in the male mice 1h after drug administration. Photomicrographs of
histological sections of lungs from mice isolated 1 h after the treatment with
UFH 300U/kg (A,B), UFH + Dex40-GTMAC3 7.5mg/kg (C,D), and UFH +
protamine 3mg/kg (E,F). Images were taken using 200× magnification.
Arrowheads indicate congestion; arrows indicate infiltration of inflammatory
cells.
because protamine induced statistically significant change in
the lowest concentration. In fact, Dex40-GTMAC3 effect was
opposite to that of protamine. Others found protective rather
than destructive effect of unmodified dextrans on the erythrocyte
membrane (Cudd et al., 1989).
Dex40-GTMAC3 will be typically administered to patient as
single injection. Therefore, we evaluated its safety in different
time points up to 28 days after single intravenous administration
of Dex40-GTMAC3 followed by UFH. Animals’ behavior and
body weight were the same as control or UFH treated group and
we did not observe any changes in the blood count and in the
clinical biochemistry during the whole experiment.
Based on our body distribution data we examined the
histopathological changes in kidney, liver and lungs of
heparinized mice 1 h and 2 days after single administration of
1ml/kg PBS solution of Dex40-GTMAC3 (0.75%) or protamine
(0.3%). We did not examine spleen in detail, because no
significant differences in spleen tissue were previously detected
in repeated-dose 1 month long experiment in mice (Kalaska
et al., 2015). In Dex40-GTMAC3-treated group we observed
slight vacuolization of proximal tubular cells. Intravenous
administration of dextrans was shown to cause reversible
renal abnormalities, characterized by vacuolization of proximal
tubular cells in human kidneys (so-called osmotic nephrosis;
Vos et al., 2002). Kitazawa et al. (2014) reported changes in liver,
FIGURE 11 | Pulmonary changes in the male rats observed 28 days
after the treatment. Photomicrographs of histological sections of lungs
isolated from rats 28 days after the administration of UFH 300U/kg (A,B),
UFH + Dex40-GTMAC3 7.5mg/kg (C,D), and UFH + protamine 3mg/kg
(E,F). Images (A,C,E) were taken using the 100× magnification and images
(B,D,F) were taken using 200× magnification. Arrowheads indicate
congestion.
lungs, spleen and kidneys, when treated rats with 10% saline
solution of 40 or 200–300 kDa dextrans in dose of 5ml/kg/day
for 28 days. Daily dose used in that study was much higher
than a dose of Dex40-GTMAC3 used in our study to neutralize
high dose of UFH (prolonging activated partial thromboplastin
time more than 15 times). Osmotic nephrosis-like lesions were
reported for other biopolymers such as hydroxyethyl starches
(Legendre et al., 1993) and gelatins (Kief, 1969). They were also
observed with agents that do not induce acute renal failure such
as mannitol and glucose (Kief, 1969).
Nashida et al. (1991) showed that the hepatic disposition
of neutral and anionic dextrans are similar. Therefore, we also
expected changes in the liver in the case of cationic dextrans,
especially because positively charged macromolecules are rapidly
taken up by the liver (Nakane et al., 1988; Nishida et al., 1990)
and enter the hepatic cells by fluid-phase endocytosis (Lake et al.,
1985; Stock et al., 1989). We noticed cytoplasmic vacuolation
of hepatocytes 1 h after drug administration. We found that
the vacuolated hepatocytes in animals are not damaged, but
they probably represent cells regenerating in response to hepatic
injury. Nayak et al. (1996) found that the hepatocytes with non-
lipid cytoplasmic vacuolization seen in acute and subacute liver
injury are cells that have adapted to the toleration of further
injury. Their vacuolation seems to be a relatively short-lived,
acute-phase adaptive response to milder forms of injury. Some
Frontiers in Pharmacology | www.frontiersin.org 10 March 2016 | Volume 7 | Article 60
Sokolowska et al. The Toxicokinetics of Cationically-Modified Dextran
FIGURE 12 | Hepatocellular changes in the male rats observed 28 days
after the treatment. Photomicrographs of histological sections of the liver
isolated from rats 28 days after administration of UFH 300U/kg (A,B), UFH +
Dex40-GTMAC3 7.5mg/kg (C,D), and UFH + protamine 3mg/kg (E,F).
Images (A,C,E) were taken using the 100× magnification and images (B,D,F)
were taken using 200× magnification. Arrowheads indicate congestion; short
arrows indicate infiltration of inflammatory cells; long arrows indicate necrotic
foci.
hepatocytes showed enlargement of both hepatocyte cytoplasm
and nuclei, not typically seen in control mice. Spontaneous
occurrence of karyocytomegaly is more common in aging mice
than in rats (Lu et al., 1993; Styles, 1993) and it is not typically
associated with increased liver weight. We did not observe such
changes in rats.
Long-term response to single injection of Dex40-GTMAC3 or
protamine to rats was analyzed in tissue sections from kidney,
liver, and lungs collected at 28th day after administration. We
did not observe detectable tissue damage, such as cell necrosis
or leukocyte infiltration in the organs from both control and
Dex40-GTMAC3 treated rats. The vacuolization of hepatocytes
and proximal tubular cells seemed to be less pronounced after
28 days in comparison to the acute response. Others also found
reversible vacuolization of hepatocytes induced by unmodified
dextrans in rats (Mehvar et al., 1994).
Interestingly, we found signs of organ damage 28 days
after single injection of protamine, presented as strong
congestion, lipid vacuoles and necrosis of hepatocytes with
nuclei degradation. Several authors have reported that protamine
may inhibit hepatic lipase activity (Harwood et al., 1974;
Berger and Abraham, 1977) or cause nephrosis resulting
in hypercholesterolemia (Saito et al., 1987). We also found
vacuolation and sometimes complete exfoliation of epithelial cells
FIGURE 13 | Changes in the cortical (A,C,E) and indigenous (B,D,F)
kidney in rats 28 days after the drug administration. Photomicrographs
of histological sections of kidneys isolated from rats 28 days after the
administration of UFH 300U/kg (A,B), UFH + Dex40-GTMAC3 7.5mg/kg
(C,D), and UFH + protamine 3mg/kg (E,F). Images were taken using 200×
magnification. Arrowheads indicate congestion; arrows indicate necrotic foci.
lining the tubular part of the nephron. Protamine is known to
have an adverse effect on the systemic circulation. Injection of
protamine resulted in capillary thrombosis and severe damage
to both glomerular and tubular epithelium (Messina et al., 1989;
Kurihara et al., 1992). Although the mechanism of protamine
nephrotoxicity is unclear, even small dose may be toxic to
the cellular components by neutralizing anionic sites in the
glomerulus and cause reversible epithelial damage and change of
renal function (Andrew, 1978; Vehanskarl et al., 1982; Adler et al.,
1983; Messina et al., 1989).
We also found diffusive intra-alveolar foam cell aggregation
in the lungs of the animals 1 h after injection of protamine.
Similarly, others reported direct toxic effect on isolated
rat lungs (Fairman et al., 1987) and in living animals,
presented as distinct hemorrhage, pulmonary edema, and
inflammatory cell infiltration (Koslow et al., 1987; Cook et al.,
1992). The mechanism of acute pulmonary toxicity probably
involves activation by UFH-protamine complexes the classical
complement pathway leading to the formation of C5a, which
causes leukoaggregation and leukoactivation, release of oxygen
free radicals and lipid peroxidation (Morel et al., 1988). Taking
together our and others results the release of thromboxane A2
by intravascular macrophages (Chang and Voelkel, 1989) leading
to vasoconstriction and activation of blood platelets in lungs
(Jenkins et al., 1971; Eika, 1972) may be the main cause of
protamine’s severe adverse effects in patients, such as pulmonary
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hypotension and bradycardia. Our results put one more red flag
on the use of this antidote and signal the need for long-term
monitoring of patients, especially receiving repeatable injections
of protamine.
In contrast to protamine-treated animals we observed only
slight congestion of the lungs after administration of Dex40-
GTMAC3. We found one report of noncardiogenic pulmonary
edema in previously healthy patient receiving dextran 40 kDa
(Kaplan and Sabin, 1975), but such pulmonary capillary leakage
and subsequent pulmonary edema were not included among the
adverse reactions of dextran 40 kDa (Data and Sies, 1974).
Our previous study (Kalaska et al., 2015) showed that Dex40-
GTMAC3 effectively reverses heparin-induced anticoagulation
without producing any of the acute adverse effects exhibited by
protamine. Moreover, it did not induce immune system response
in contrast to protamine (Bakchoul et al., 2013), heparinase
I (Stafford-Smith et al., 2005), lactoferrin (Wu et al., 1995)
or low molecular weight protamine (Chang et al., 2001). The
safety of other alternative UFH antidotes such as haxadimetrine
bromide (Ransdell et al., 1965), methylene blue (Kikura et al.,
1996; Ginimuge and Jyothi, 2010), vancomycin (Kikura et al.,
1996), lactoferin (Wu et al., 1995), or chemically-modified
inactive antithrombin (Fazavana et al., 2013) were not sufficiently
examined in animals and they all failed in the later phases
of drug discovery. Our present study provides toxicokinetic
profile of Dex40-GTMAC3—a potential UFH reversal agent. The
research and development costs for Dex40-GTMAC3 should be
also significantly lower than those of protein-based antidotes
such as protamine or andexanet alfa. Our histopathology results
in the protamine-treated animals indicate the need for closer
observation of its long-term effects, especially in patients with
liver or renal insufficiency.
Taking together all of our studies on the cationically-modified
dextrans, we are introducing here Dex40-GTMAC3—a new
highly effective and safer than protamine candidate for the
reversal of unfractionated heparin. We are aware that the safety
in rodents and humans may differ and our results need to
be verified on larger mammals before entering clinical trials.
We hope that superior to protamine pharmacological profile of
Dex40-GTMAC3 will address the unmet need for a new efficient
and safer antidote of UFH.
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